Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
about
Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLCRole of HER2 in NSCLCThe minority report: targeting the rare oncogenes in NSCLCTherapeutic vaccines in non-small cell lung cancerCIViC databaseTrastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance.Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.Frequency of HER2/neu overexpression in adenocarcinoma of the gastrointestinal system.Lung cancer immunotherapy.Targeted therapy in NSCLC driven by HER2 insertionsTranscriptional expression of 8 genes predicts pathological response to first-line docetaxel + trastuzumab-based neoadjuvant chemotherapy.p95HER2 truncated form in resected non-small cell lung cancerThe frequency and clinical impact of HER2 alterations in lung adenocarcinoma.Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations.Present and future of lung cancer vaccines.Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.Rare mutations in non-small-cell lung cancer.HER2 and lung cancer.Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC).Immunotherapy prospects in the treatment of lung cancer and mesothelioma.Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.Assays for predicting and monitoring responses to lung cancer immunotherapy.Emerging targeted therapies in non-small cell lung cancer.HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.Immune Therapy.Expanded molecular interrogation for potential actionable targets in non-squamous non-small cell lung cancer.Understanding and targeting resistance mechanisms in NSCLC.Antigen-Presenting Intratumoral B Cells Affect CD4+ TIL Phenotypes in Non-Small Cell Lung Cancer Patients.[Research Progress of Targeted Therapy for Anaplastic Lymphoma Kinase and Other Rare Driver Genes in Advanced Non-small Cell Lung Cancer].Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.[Detecting overexpression level of HER2 gene in NSCLC by real-time quantitative PCR and the 2[-Delta Delta C(T)] method].
P2860
Q26747276-2C2EF16D-DAE2-43EE-BDEF-FC8B01C36A5BQ26781683-32E19C44-5DBB-4B18-99DF-5B47325802E2Q26851636-ED3E7574-6640-4C2F-8BD2-E7617D697317Q26864896-C609074B-6953-43B0-A89E-A91E9821F598Q27612411-0947F998-F853-4B7B-A288-506BEB259703Q27853015-1F74BA28-CEB2-4A84-A747-E5CDB81D761EQ27853282-EBF89D27-B24E-49A2-B597-C706B7185ADDQ33626875-8F613EBF-5290-4BB0-8AEE-BCE1759B3A2EQ34146503-773C6092-0025-4064-AF33-8EE4C0C3B525Q35200528-C2680E95-F32B-447E-9C71-84064A071A51Q35562526-AB43EA4F-55D5-483D-B884-20B4E0A14C64Q36170889-71CF43E4-5AFA-48EF-8FB4-7B61CE6F6D80Q36266449-3F0F692E-D589-4579-89DA-D510DEBC97FEQ36495936-A66E06A5-D407-4BBF-A9FE-78A3521DB669Q36580586-B4DA079E-CD24-47AD-A655-ADB71EAE9189Q36785721-288C7AF0-EE7A-4C27-BD76-4FDC00CBC013Q38104414-EC68024F-504F-4389-852A-D5F6AABD7666Q38153447-BCABBBCD-B83A-4682-8610-B0D389EA47ABQ38358410-370D3711-2D4B-47B1-9442-AE58D1BA74D5Q38390104-99D34A76-68C1-4870-AECB-6CD20E1AA345Q38514601-3027AE20-1EDB-4D70-A89C-0E05C629427BQ38547391-3CCC6C2D-23B2-4F51-9BE8-2A5652A814D6Q38653045-EA9B84C8-552A-463E-BA10-0EFF998443D9Q38661973-B5CA2777-7A3B-45EE-8E4C-F631B0817986Q38669273-E536DCC2-C2AB-435E-9EBC-2D9136412D63Q45907759-145BFCF1-B66E-45FD-8426-038FB86BFF79Q46915997-269138D1-D96D-4393-BFFA-916BBE12A8A8Q52757687-ACE142DC-E642-4F57-80CE-1CC09B61FCCBQ53565079-39F41907-E40F-4FC5-8590-F8E1A4FD36AEQ53702598-E67A287C-4267-44A4-81A6-37DAFEE84ABEQ54334966-FE207DB1-D422-4CF1-8E39-0AA322300EAC
P2860
Trastuzumab plus docetaxel in HER2/neu-positive non-small-cell lung cancer: a California Cancer Consortium screening and phase II trial.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@ast
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@en
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@nl
type
label
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@ast
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@en
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@nl
prefLabel
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@ast
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@en
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@nl
P2093
P3181
P356
P1433
P1476
Trastuzumab plus docetaxel in ...... screening and phase II trial.
@en
P2093
Derick H M Lau
James H Doroshow
Jeff Longmate
Luko Laptalo
Paul H Gumerlock
Primo N Lara
Regina Gandour-Edwards
P3181
P356
10.3816/CLC.2004.N.004
P407
P577
2004-01-01T00:00:00Z